Novo Nordisk A/S vs iShares TIPS Bond ETF — how do they compare? Novo Nordisk A/S trades at $47.18 (market cap $207.31B), while iShares TIPS Bond ETF trades at $106.95. The key difference: Novo Nordisk A/S pays a 3.76% dividend while iShares TIPS Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TIP | |
|---|---|---|
Market Cap | $207.31B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $112.20 |
52-Week Low | $35.29 | $106.86 |
Enterprise Value | $222.02B | — |
Dividend Yield | 3.76% | — |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
TIP trades at $107.08 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces headwinds from broader market concerns about inflation and Federal Reserve policy. Recent dividend distributions provide some shareholder return, but key financial ratios remain undisclosed, limiting fundamental visibility.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Investment opportunity hinges on inflation trends and Fed policy clarity, while risks include prolonged bond market volatility and energy price impacts. Wall Street sentiment appears mixed with technical weakness offset by dividend stability.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →